Piperazine ferulate and other five drugs have applied for withdrawal due to the rising cost

[industry trends of pharmaceutical Station] on April 23, Hainan public resources trading service center issued the notice on publicizing the information of newly added and removed drugs (hereinafter referred to as the notice) It can be seen from "drug information of some enterprises applying for cancellation of Internet access" that the newly added Internet access drugs include amlodipine besylate tablets, atorvastatin calcium tablets, montelukast sodium tablets, cefuroxime ester tablets and other 25 over consistency evaluation drugs However, piperazine ferulate tablets, tripitol tablets, lithium carbonate tablets, heparin sodium injection, bupivacaine hydrochloride injection 5 drugs applied for withdrawal due to the rising cost Valaciclovir hydrochloride granules, terbinafine hydrochloride cream and Zhongfeng Huichun tablets were also withdrawn due to the enterprise's suspension of production of corresponding specifications In addition, six drugs were removed from the network due to the transfer of production approval documents, adjustment of production and stock up, technical improvement, expiration of import drug registration certificate and other reasons Cost increase has become one of the main reasons for many enterprises to "cut off supply" In fact, since this year, there have been many drugs that have been removed from the Internet due to factors such as rising cost and production line transformation For example, at the end of January this year, Gansu Province issued the notice on canceling the qualification of winning the bid and hanging the net for some drugs According to the notice, 9 drugs from 9 enterprises have been unable to guarantee the normal supply of medical institutions in Gansu Province due to the transformation of production lines and the increase of costs They have applied for suspension or cancellation of the bid On March 6, Gansu public resources trading network issued the notice of canceling the qualification of some drugs winning the bid to be linked to the network According to the notice, seven drugs of six enterprises, such as butorphanol tartrate nasal spray of Hengrui pharmaceutical, Zhupo powder of Baohetang pharmaceutical, and Ankahuangmin capsule of Lanzhou foci pharmaceutical, have been unable to guarantee the normal supply of medical institutions due to production line transformation, cost rise and other reasons Therefore, pharmaceutical enterprises take the initiative to apply for the cancellation of drug Internet In addition to Hainan and Gansu Province, Shaanxi, Ningxia, Inner Mongolia, Jiangxi and other places have also issued the notice of canceling the qualification of drug network, and the reasons for canceling the network include non-compliance, rising raw materials, production line transformation, environmental pollution, failure to pass the consistency evaluation and other factors In February, Shaanxi public resources Trading Center released the announcement on the adjustment of drug information for some online transactions Among them, 10 drugs were suspended or directly withdrawn from the network due to non-compliance with the regulations, 2 of them were suspended from the network due to ornidazole sodium chloride injection, and 8 of them were withdrawn from the network On January 22, Ningxia pharmaceutical centralized purchase network issued the notice on canceling the qualification of winning the bid (hanging the net) for 48 drugs of erdosten capsule and other products, and the enterprise applied for canceling 48 drugs of hanging the net Among them, 23 drugs are not bidding temporarily, 20 drugs are low-cost, and 1 drug is directly on the Internet On January 11, Inner Mongolia pharmaceutical purchasing platform also issued the notice on announcing the application of Hunan Dongting Pharmaceutical Co., Ltd and other enterprises to cancel the qualification of drug Internet access Due to the rise of raw materials, production line transformation, environmental pollution and other reasons, 7 pharmaceutical enterprises applied to cancel 14 drug Internet access qualifications   In addition, on January 25, Jiangxi Medical Procurement Service Center issued the notice on adjusting the online procurement qualification of some drugs in Jiangxi Province in 2019, among which, the metformin hydrochloride sustained-release tablets of 15 pharmaceutical companies including Chengdu Hengrui Pharmaceutical Co., Ltd and Zhengda Tianqing, and the Amoxicillin Capsules of Zhejiang Asia Pacific Pharmaceutical Co., Ltd and Kunming Baker Norton Pharmaceutical Co., Ltd failed to pass The network is suspended due to consistency evaluation It can be seen that for pharmaceutical enterprises, it is very important to pass the consistency evaluation The drugs that pass the consistency evaluation have the qualification to be directly linked to the Internet, while those that fail may be removed from the Internet.